Corvus Pharmaceuticals, Inc. (CRVS)
Nasdaq: CRVS · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2014
Who owns Corvus Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
5
Orbimed Advisors LLC holds 10.3% of COMMON STOCK, as its SCHEDULE 13D/A filed Jan 27, 2026 says.
Directors and officers
12
report now, of 23 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Orbimed Advisors LLC
SCHEDULE 13D/A · filed Jan 27, 2026 · COMMON STOCK · 12.2% in May 14, 2025
Richard A. Miller
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, $0.0001 par value per share · 7.7% in Feb 13, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 27, 2026 · Common Stock · 6.4% in Apr 27, 2026
Sirenia Capital Management LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, par value $0.0001 per share
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Adams Street Partners, LLC
SCHEDULE 13D/A · filed Feb 5, 2026 · Common Stock · reported falling below 5%
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 5.18% in Jan 30, 2026
Samlyn Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6% in May 15, 2025
What CRVS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Angel Pharmaceuticals LTD Equity Method Investee
An investee · investee · invested in, named in the 10-K filed Mar 12, 2026
2 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 12, 2026.
Insider tradesForm 4
0sales
3purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 26 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Miller Richard A Md | President and CEO | 0 | $0 | 0 | 2 | $100,000 |
| Moore David Scott | director | 0 | $0 | 0 | 1 | $300,000 |